PriceTargets.com logo

Editas Medicine - EDIT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $7.00
  • Forecasted Upside: 434.35%
  • Number of Analysts: 14
  • Breakdown:
  • 2 Sell Ratings
  • 9 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.31 As of 12/20/2024 06:45 PM ET
▼ -0.03 (-2.24%)

This chart shows the closing price for EDIT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Editas Medicine Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EDIT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EDIT

Analyst Price Target is $7.00
▲ +434.35% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is $7.00, with a high forecast of $15.00 and a low forecast of $1.00. The average price target represents a 434.35% upside from the last price of $1.31.

This chart shows the closing price for EDIT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 14 polled investment analysts is to hold stock in Editas Medicine. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 2 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/16/2024Evercore ISILower TargetOutperform ➝ Outperform$7.00 ➝ $5.00
12/16/2024JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
12/13/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$5.00 ➝ $4.00
12/13/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$5.00 ➝ $3.00
12/13/2024Chardan CapitalReiterated RatingBuy ➝ Neutral
12/13/2024Robert W. BairdLower TargetOutperform ➝ Outperform$10.00 ➝ $8.00
12/13/2024Stifel NicolausDowngradeBuy ➝ Hold$11.00 ➝ $3.00
12/13/2024Truist FinancialDowngradeBuy ➝ Hold
12/11/2024Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$7.00 ➝ $4.00
11/25/2024Bank of AmericaDowngradeBuy ➝ Underperform$13.00 ➝ $1.00
11/6/2024Evercore ISIUpgradeIn-line ➝ Outperform
11/5/2024Chardan CapitalReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
11/5/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$8.00 ➝ $5.00
11/5/2024Stifel NicolausLower TargetBuy ➝ Buy$17.00 ➝ $11.00
11/5/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$9.00 ➝ $7.00
11/5/2024Truist FinancialLower TargetBuy ➝ Buy$12.00 ➝ $8.00
11/5/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$7.00 ➝ $5.00
11/4/2024Raymond JamesDowngradeOutperform ➝ Market Perform
10/23/2024Evercore ISILower TargetIn-Line ➝ In-Line$7.00 ➝ $3.00
10/23/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$27.00 ➝ $9.00
10/22/2024Chardan CapitalLower TargetBuy ➝ Buy$20.00 ➝ $12.00
9/19/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$8.00 ➝ $8.00
8/8/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$9.00 ➝ $7.00
8/8/2024Truist FinancialLower TargetBuy ➝ Buy$20.00 ➝ $12.00
8/8/2024Bank of AmericaUpgradeNeutral ➝ Buy$13.00 ➝ $15.00
6/18/2024OppenheimerReiterated RatingMarket Perform ➝ Market Perform$12.00 ➝ $12.00
5/30/2024Evercore ISILower TargetIn-Line ➝ In-Line$15.00 ➝ $7.00
5/9/2024CitigroupLower TargetBuy ➝ Buy$16.00 ➝ $15.00
5/9/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$11.00 ➝ $9.00
5/9/2024Morgan StanleyUpgradeUnderweight ➝ Equal Weight$7.00
2/29/2024CitigroupBoost TargetBuy ➝ Buy$11.00 ➝ $16.00
2/29/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$10.00 ➝ $11.00
2/27/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$8.00 ➝ $9.00
12/12/2023Truist FinancialBoost TargetBuy ➝ Buy$15.00 ➝ $20.00
10/24/2023CitigroupUpgradeNeutral ➝ Buy$11.00
10/18/2023JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$8.00
10/17/2023Cantor FitzgeraldDowngradeOverweight ➝ Neutral
9/28/2023Stifel NicolausUpgradeHold ➝ Buy$9.00 ➝ $17.00
9/13/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$14.00
8/29/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$14.00
8/3/2023OppenheimerReiterated RatingMarket Perform ➝ Market Perform$12.00
8/2/2023Chardan CapitalLower TargetBuy ➝ Buy$22.00 ➝ $19.00
6/12/2023Raymond JamesUpgradeMarket Perform ➝ Outperform$17.00
2/23/2023Credit Suisse GroupBoost TargetNeutral$13.00 ➝ $15.00
2/23/2023Royal Bank of CanadaLower TargetSector Perform$14.00 ➝ $10.00
2/23/2023Chardan CapitalLower TargetBuy$35.00 ➝ $22.00
2/23/2023Wells Fargo & CompanyLower Target$36.00 ➝ $30.00
1/31/2023Cantor FitzgeraldInitiated CoverageOverweight$15.00
1/24/2023Morgan StanleyLower TargetUnderweight$8.00 ➝ $7.00
1/23/2023Leerink PartnersBoost TargetMarket Perform$6.00 ➝ $7.00
1/10/2023Leerink PartnersLower TargetMarket Perform$7.00 ➝ $6.00
1/4/2023Wells Fargo & CompanyLower TargetOverweight$50.00 ➝ $36.00
12/13/2022CitigroupInitiated CoverageNeutral$11.00
12/6/2022Credit Suisse GroupReiterated RatingNeutral$13.00
11/21/2022Evercore ISILower Target$8.00
11/18/2022Bank of AmericaLower TargetNeutral$18.00 ➝ $15.00
11/18/2022Morgan StanleyLower TargetUnderweight$10.00 ➝ $8.00
11/18/2022Royal Bank of CanadaLower TargetSector Perform$32.00 ➝ $14.00
11/18/2022Truist FinancialLower TargetBuy$80.00 ➝ $35.00
11/18/2022Robert W. BairdLower TargetOutperform$25.00 ➝ $18.00
11/17/2022Credit Suisse GroupDowngradeOutperform ➝ Neutral$25.00 ➝ $13.00
11/17/2022Chardan CapitalLower TargetBuy$43.00 ➝ $35.00
11/17/2022OppenheimerDowngradeOutperform ➝ Market Perform$28.00 ➝ $12.00
11/17/2022Leerink PartnersLower TargetMarket Perform$14.00 ➝ $7.00
11/8/2022Morgan StanleyLower TargetUnderweight$15.00 ➝ $10.00
11/3/2022Royal Bank of CanadaLower TargetSector Perform$40.00 ➝ $32.00
11/3/2022Robert W. BairdLower TargetOutperform$30.00 ➝ $25.00
11/3/2022Leerink PartnersLower TargetMarket Perform$14.00 ➝ $12.00
11/2/2022Chardan CapitalLower TargetBuy$60.00 ➝ $43.00
9/29/2022Bank of AmericaInitiated CoverageNeutral$18.00
8/4/2022BarclaysBoost TargetEqual Weight$16.00 ➝ $17.00
5/24/2022The Goldman Sachs GroupLower TargetSell$10.00 ➝ $8.00
5/5/2022OppenheimerLower Target$55.00 ➝ $28.00
4/18/2022Robert W. BairdLower Target$44.00 ➝ $33.00
4/12/2022Morgan StanleyBoost TargetUnderweight$16.00 ➝ $17.00
2/25/2022BarclaysLower Target$39.00 ➝ $18.00
2/25/2022Chardan CapitalLower TargetBuy$75.00 ➝ $60.00
2/25/2022OppenheimerLower TargetOutperform$80.00 ➝ $55.00
2/25/2022Leerink PartnersLower TargetMarket Perform$41.00 ➝ $27.00
2/11/2022Evercore ISIDowngradeHold$15.00
1/6/2022Morgan StanleyLower TargetUnderweight$37.00 ➝ $24.00
10/20/2021Robert W. BairdReiterated RatingBuy
10/19/2021Leerink PartnersInitiated CoverageMarket Perform$41.00
9/30/2021Chardan CapitalReiterated RatingBuy$75.00
9/30/2021Stifel NicolausLower TargetHold$65.00 ➝ $46.00
9/23/2021Stifel NicolausInitiated CoverageHold$65.00
9/9/2021OppenheimerUpgradeMarket Perform ➝ Outperform$42.00 ➝ $80.00
8/9/2021Truist FinancialUpgradeBuy$80.00
8/5/2021Evercore ISIUpgradeUnderperform ➝ Outperform$20.00 ➝ $60.00
7/7/2021Chardan CapitalReiterated RatingBuy
5/10/2021Morgan StanleyLower TargetUnderweight$40.00 ➝ $37.00
5/3/2021Royal Bank of CanadaInitiated CoverageSector Perform$40.00
4/16/2021The Goldman Sachs GroupInitiated CoverageSell$20.00
3/22/2021Credit Suisse GroupInitiated CoverageOutperform$58.00
3/8/2021BarclaysReiterated RatingOverweight ➝ Equal Weight$46.00
3/2/2021Morgan StanleyLower TargetUnderweight$45.00 ➝ $40.00
3/1/2021BarclaysDowngradeOverweight ➝ Equal Weight$46.00
2/28/2021JPMorgan Chase & Co.Reiterated RatingSell$30.00
2/26/2021Truist FinancialDowngradeBuy ➝ Hold$45.00
2/25/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$30.00
2/10/2021Chardan CapitalBoost TargetBuy$55.00 ➝ $77.00
1/20/2021JPMorgan Chase & Co.Reiterated RatingHold
1/19/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight$64.00 ➝ $45.00
1/13/2021Wells Fargo & CompanyBoost TargetOverweight$69.00 ➝ $86.00
1/7/2021Raymond JamesDowngradeOutperform ➝ Market Perform
12/16/2020Morgan StanleyBoost TargetEqual Weight$30.00 ➝ $64.00
12/10/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$28.00 ➝ $69.00
11/11/2020Morgan StanleyLower TargetEqual Weight$31.00 ➝ $30.00
11/6/2020Raymond JamesLower TargetOutperform$65.00 ➝ $60.00
11/2/2020Robert W. BairdInitiated CoverageUnderperform$14.00
10/13/2020Morgan StanleyLower TargetEqual Weight$32.00 ➝ $31.00
8/10/2020Morgan StanleyBoost TargetEqual Weight$27.00 ➝ $32.00
8/7/2020Raymond JamesBoost TargetOutperform$46.00 ➝ $65.00
6/18/2020SunTrust BanksInitiated CoverageBuy$45.00
6/15/2020OppenheimerReiterated RatingHold
6/12/2020Chardan CapitalReiterated RatingBuy$55.00
5/11/2020Morgan StanleyLower TargetEqual Weight$30.00 ➝ $27.00
5/7/2020OppenheimerInitiated CoverageHold
3/4/2020Chardan CapitalReiterated RatingBuy$55.00
2/27/2020Raymond JamesLower TargetOutperform$44.00 ➝ $41.00
2/27/2020JPMorgan Chase & Co.Reiterated RatingHold
2/21/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$28.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.06 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 21 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
5/25/2024
  • 7 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 6 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 10 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 5 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 10 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 9 very positive mentions
  • 21 positive mentions
  • 8 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 6 very positive mentions
  • 25 positive mentions
  • 19 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 6 very positive mentions
  • 25 positive mentions
  • 19 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Editas Medicine logo
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.31
Low: $1.28
High: $1.38

50 Day Range

MA: $2.58
Low: $1.31
High: $3.76

52 Week Range

Now: $1.31
Low: $1.28
High: $11.58

Volume

4,216,381 shs

Average Volume

2,049,668 shs

Market Capitalization

$108.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.86

Frequently Asked Questions

What sell-side analysts currently cover shares of Editas Medicine?

The following Wall Street analysts have issued reports on Editas Medicine in the last year: Bank of America Co., Barclays PLC, Chardan Capital, Citigroup Inc., Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Raymond James, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, Truist Financial Co., and Wells Fargo & Company.
View the latest analyst ratings for EDIT.

What is the current price target for Editas Medicine?

0 Wall Street analysts have set twelve-month price targets for Editas Medicine in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 434.4%. Citigroup Inc. has the highest price target set, predicting EDIT will reach $15.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $1.00 for Editas Medicine in the next year.
View the latest price targets for EDIT.

What is the current consensus analyst rating for Editas Medicine?

Editas Medicine currently has 2 sell ratings, 9 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in EDIT, but not buy more shares or sell existing shares.
View the latest ratings for EDIT.

What other companies compete with Editas Medicine?

Other companies that are similar to Editas Medicine include MeiraGTx, Esperion Therapeutics, Monte Rosa Therapeutics, Cartesian Therapeutics and Organogenesis. Learn More about companies similar to Editas Medicine.

How do I contact Editas Medicine's investor relations team?

Editas Medicine's physical mailing address is 11 Hurley Street, Cambridge MA, 02141. The company's listed phone number is (617) 401-9000 and its investor relations email address is [email protected]. The official website for Editas Medicine is www.editasmedicine.com. Learn More about contacing Editas Medicine investor relations.